Accendra Health stock falls 12.90 percent on NYSE

Published on 10/15/2026 at 20:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Accendra Health stock costs EUR 0.24 on October 15, 2026 at 8:44 p.m. CEST, down 12.90 percent on the NYSE. Earnings follow October 29.

Trading and reporting dates

The NYSE quote reached USD 0.27 on October 15, 2026.
Zacks lists October 29, 2026 as the estimated next earnings date.
Accendra Health stock costs EUR 0.24 at Lang & Schwarz on October 15, 2026 at 8:44 p.m. CEST, down 12.90 percent on the NYSE.

ACH, US6907321029, Illustration mit AI erstellt.

Accendra Health stock fell 12.90 percent on the NYSE on October 15, 2026, as the home-market quote moved from USD 0.31 to USD 0.27. The euro quote was EUR 0.24 at Lang & Schwarz on October 15, 2026 at 8:44 p.m. CEST.

October 29 earnings date

Zacks lists October 29, 2026 as the estimated date for Accendra Health's next earnings release. The page also gives a consensus estimate of a loss of USD 0.05 per share for the quarter ending September 2026.

The timing gives the stock a defined event on the calendar after a sharp decline in the home-market quote. Accendra Health's investor-relations page identifies the company as the renamed successor to Owens & Minor and says its common stock trades on the New York Stock Exchange under ACH.

Price position after the decline

The NYSE quote stood at USD 0.27 on October 15, 2026 at 2:49 p.m. ET, while the latest euro indication was EUR 0.24 at Lang & Schwarz at 8:44 p.m. CEST. The Lang & Schwarz bid was EUR 0.24 and the ask was EUR 0.25 at that timestamp.

The USD 0.27 home-market quote matched the reported 52-week low of USD 0.27 on October 15, 2026. The 52-week high was USD 5.60, putting the low at a wide distance from the top of the reported range. Accendra Health's market capitalization was USD 20.9 million on the same date.

Valuation and reporting calendar

Accendra Health's latest quarterly figures for the period ended June 30, 2026 included revenue of USD 613.2 million, operating profit of minus USD 35.2 million and net income of minus USD 89.1 million. The operating margin was minus 6.00 percent for the quarter.

The company describes its business as a combination of healthcare products and services and patient-direct care, including diabetes management, respiratory support and sleep apnea products. Its investor-relations page presents the second-quarter 2026 materials and the company's home-based care strategy through Accendra Health.

Comparison with peers

ACH (NYSE, USD): down 12.90 percent, market capitalization USD 20.9 million.

Insulet (Nasdaq, USD): up 3.37 percent, P/E 25.89, market capitalization USD 9.6 billion.

Henry Schein (Nasdaq, USD): up 1.51 percent, P/E 25.32, market capitalization USD 9.7 billion.

Trading frame

Accendra Health's small market capitalization and the reported 52-week low make the October 29 earnings date the next concrete calendar marker for the stock. The next report will put the June-quarter revenue and operating result into a newer period context.

At Lang & Schwarz, Accendra Health stock was trading at EUR 0.24 on October 15, 2026 at 8:44 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Accendra Health stock.